Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZLX-1
- Development stage
- Preclinical
- Lead developer
- Blake Insomnia Therapeutics
- Modality
- Small Molecules
01
Overview
ZLX-1 is an investigational insomnia therapy being developed by Blake Insomnia Therapeutics as a patent‑pending compound aimed at treating sleep disorders without the next‑day residual effects and other side effects that limit current insomnia drugs.[7][10] Publicly available information characterizes ZLX-1 as a novel small-molecule candidate for insomnia, but detailed target, receptor pharmacology, and full mechanistic data have not been disclosed; company communications emphasize efficacy in preclinical or early clinical testing with an improved tolerability profile relative to existing hypnotics.[7][10]
- Brand names
- Zleepax
02
Targets
ADRB1 (β1)
Beyond the preview
Go deeper on ZLX-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZLX-1.